Rifampicin

Generic Name: Rifampicin

Brand Names: Isonarif, Rifadin, Rifamate, Rifater, Rofact

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₈N_₄O_₁₂

CAS Number: 13292-46-1

Unique Ingredient Identifier: VJT6J7R4TR

Background: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericid...

Indication: Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.

Associated Conditions: Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis

Associated Therapies: Antibacterial therapy

Clinical Trials

To Evaluate if Multiple Doses of Rifampicin Change the Blood Concentration of YM150 (Darexaban)

Phase 1

Completed

Conditions: Pharmacokinetics of Darexaban and Metabolites
Healthy Subjects

Interventions: Drug: darexaban
Drug: Rifampicin

First Posted Date: 2011-07-29

Last Posted Date: 2013-04-11

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 26

Registration Number: NCT01406002

Locations: 🇫🇷
SGS Aster, Paris, France

Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: Linifanib
Drug: Rifampin

First Posted Date: 2011-07-26

Last Posted Date: 2011-11-02

Lead Sponsor: Abbott

Target Recruit Count: 14

Registration Number: NCT01401933

Locations: 🇺🇸
Site Reference ID/Investigator# 49952, Madison, Wisconsin, United States
🇺🇸
Site Reference ID/Investigator# 49953, Tucson, Arizona, United States

A Study to Evaluate the Effects of Rifampin on Single-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Rifampin
Drug: Canagliflozin

First Posted Date: 2011-07-18

Last Posted Date: 2013-05-06

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 14

Registration Number: NCT01395927

Drug Interaction Study With Rifampicin and Afatinib

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Afatinib
Drug: Rifampicin

First Posted Date: 2011-07-18

Last Posted Date: 2014-06-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 22

Registration Number: NCT01396265

Locations: 🇩🇪
1200.152.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Safety, Tolerability, Extended Early Bactericidal Activity and PK of Higher Doses Rifampicin in Adults With Pulmonary TB

Phase 2

Completed

Conditions: Pulmonary Tuberculosis (TB)

Interventions: Drug: Rifampicin

First Posted Date: 2011-07-13

Last Posted Date: 2018-11-26

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 128

Registration Number: NCT01392911

Locations: 🇿🇦
TASK Applied Science, Bellville, South Africa
🇿🇦
University of Cape Town Lung Institute, Mowbray, South Africa

Genetic Variability in the Response to Warfarin at Baseline and During Induction of CYP2C9

Not Applicable

Conditions: Healthy Subjects

Interventions: Drug: Rifampicin

First Posted Date: 2011-07-06

Last Posted Date: 2011-07-06

Lead Sponsor: Hadassah Medical Organization

Target Recruit Count: 150

Registration Number: NCT01388075

Locations: 🇮🇱
Hadassah Hebrew University Medical Center, Jerusalem, Israel

Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)

Phase 2

Terminated

Conditions: Cystic Fibrosis
Methicillin-resistant Staphylococcus Aureus

Interventions: Drug: Rifampin
Drug: Trimethoprim/Sulfamethoxazole
Drug: Minocycline
Drug: Mupirocin
Drug: chlorhexidine gluconate oral rinse
Drug: 2% Chlorhexidine solution wipes
Behavioral: Environmental Decontamination

First Posted Date: 2011-05-06

Last Posted Date: 2017-05-15

Lead Sponsor: University of North Carolina, Chapel Hill

Target Recruit Count: 47

Registration Number: NCT01349192

Locations: 🇺🇸
St. Louis Children's Hospital, St. Louis, Missouri, United States
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
The Children's Hospital, Aurora, Colorado, United States

and more 10 locations

TMC207 +/- Rifabutin/Rifampin

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Drug: Rifabutin
Drug: Rifampin
Drug: TMC207

First Posted Date: 2011-04-25

Last Posted Date: 2017-04-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 33

Registration Number: NCT01341184

Locations: 🇺🇸
Case Western Reserve University - Case Medical Center - Infectious Disease & HIV Medicine, Cleveland, Ohio, United States

Effects of Administration of Fostamatinib on Blood Concentrations of Rifampicin in Healthy Subjects.

Phase 1

Completed

Conditions: Healthy Volunteers
Rheumatoid Arthritis

Interventions: Drug: fostamatinib
Drug: rifampicin

First Posted Date: 2011-04-15

Last Posted Date: 2011-07-22

Lead Sponsor: AstraZeneca

Target Recruit Count: 15

Registration Number: NCT01336218

Locations: 🇺🇸
Research Site, Overland Park, Kansas, United States

Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

Phase 1

Completed

Conditions: Hematologic Malignancy
Malignant Lymphoma

Interventions: Drug: Romidepsin
Drug: Rifampin

First Posted Date: 2011-03-29

Last Posted Date: 2019-11-25

Lead Sponsor: Celgene

Target Recruit Count: 14

Registration Number: NCT01324323

Locations: 🇬🇧
Sarah Cannon Research UK, London, United Kingdom
🇺🇸
Sarah Canon Research Institute, Nashville, Tennessee, United States
🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy